Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shih, C.-C.
Right arrow Articles by Hsieh, W.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shih, C.-C.
Right arrow Articles by Hsieh, W.-C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2000; 93: 245-251
© 2000 Association of Physicians

Cryptococcal meningitis in non-HIV-infected patients

C.-C. Shih, Y.-C. Chen, S.-C. Chang, K.-T. Luh1 and W.-C. Hsieh

From the Departments of Internal Medicine and 1 Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

Received 29 October 1999 and in revised form 10 February 2000

There are few reports on cryptococcal meningitis in non-HIV-infected patients in subtropical areas. We reviewed 94 non-HIV-infected patients microbiologically diagnosed with cryptococcal meningitis and hospitalized at National Taiwan University Hospital, 1977–1996. Forty-two patients (44.7%) had underlying diseases. The main initial manifestations were headache (86.2%), vomiting (72.3%) and fever (69.1%). The 30 patients with T-cell suppression had more acute illnesses (median duration of symptoms: 14 days vs. 29 days), less typical presentations of meningitis, and reduced inflammatory responses compared with the 64 without T cell suppression. There was no statistical difference between patients who received amphotericin B treatment for 10 weeks and those received amphotericin B with subsequent fluconazole treatment, in terms of mortality rate and recurrence rate. Seventy-five patients (79.8%) had satisfactory clinical responses, and two relapsed. Eighteen patients died (19.1%) and 10 of these died within 2 weeks of hospitalization. Patients in this series had outcomes comparable with those from temperate and even tropical countries with high percentages of immunocompetent hosts. Factors significantly associated with death were lymphoma, semicoma, leukocytosis, and initial high titres of cryptococcal antigen in cerebral spinal fluid (especially >=1 : 512). On multivariate analysis, lymphoma and initial high cryptococcal antigen titres were independent predictors of mortality.

Address correspondence to Dr S.-C. Chang, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan. e-mail: sc4030{at}ha.mc.ntu.edu.tw

Present address: Department of Internal Medicine, Koo Foundation, Sun Yat-Sen Cancer Center Hospital


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
C.-Y. Chen, R. N. Kumar, Y.-H. Feng, C.-H. Ho, J.-Y. You, C.-C. Liao, C.-H. Tseng, P. Mavros, W. C. Gerth, and Y.-C. Chen
Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan
J. Antimicrob. Chemother., June 1, 2006; 57(6): 1181 - 1188.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
S.-S. Jean, C.-T. Fang, W.-Y. Shau, Y.-C. Chen, S.-C. Chang, P.-R. Hsueh, C.-C. Hung, and K.-T. Luh
Cryptococcaemia: clinical features and prognostic factors
QJM, August 1, 2002; 95(8): 511 - 518.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.